Emergent BioSolutions sells Baltimore-Camden facility to Bora for $30M

Emergent BioSolutions Inc.

Sale of drug product facility to Bora Pharmaceuticals affiliate for total value of ~$30 million.
Approximately 350 Emergent employees expected to join Bora as part of the transaction.
Deal is part of multi-year plan to reduce debt, improve profitability, and streamline manufacturing to Lansing and Winnipeg.
Closing expected in Q3 2024, subject to customary conditions; Truist Securities and Covington & Burling advised Emergent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.